Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lucid Diagnostics Inc. (LUCD : NSDQ)

• Company Description    Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK. Number of Employees: 72

• Price / Volume Information    Yesterday's Closing Price: $1.18 Daily Weekly Monthly 20 Day Moving Average: 1,411,094 shares Shares Outstanding: 108.19 (millions) Market Capitalization: $127.66 (millions) Beta: 1.23 52 Week High: $1.80 52 Week Low: $0.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.92% -13.30% 12 Week -2.48% -17.97% Year To Date 44.13% 34.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 360 MADISON AVENUE 25TH FLOOR - NEW YORK,NY 10017 USA ph: 917-813-1828 fax: - mjr@pavmed.com http://www.luciddx.com

• General Corporate Information    Officers Lishan Aklog - Chief Executive Officer & Chairman Stanley N. Lapidus - Vice Chairman & Director Dennis M. McGrath - Chief Financial Officer Debra J. White - Director James L. Cox - Director Peer Information Lucid Diagnostics Inc. (ABMD) Lucid Diagnostics Inc. (DMDS) Lucid Diagnostics Inc. (CPWY.) Lucid Diagnostics Inc. (EQUR) Lucid Diagnostics Inc. (ECIA) Lucid Diagnostics Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 54948X109 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 108.19 Most Recent Split Date: (:1) Beta: 1.23 Market Capitalization: $127.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 30.59 EPS Growth vs. Year Ago Period: 26.09% vs. Previous Quarter: 19.05% Sales Growth vs. Year Ago Period: -17.28% vs. Previous Quarter: -30.83% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -124.27 12/31/24 - -124.09 Current Ratio 06/30/25 - - 03/31/25 - 0.75 12/31/24 - 1.07 Quick Ratio 06/30/25 - - 03/31/25 - 0.74 12/31/24 - 1.05 Operating Margin 06/30/25 - - 03/31/25 - -895.06 12/31/24 - -852.83 Net Margin 06/30/25 - - 03/31/25 - -1,699.86 12/31/24 - -1,047.61 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,481.55 12/31/24 - -1,047.61 Book Value 06/30/25 - - 03/31/25 - -0.57 12/31/24 - -0.78 Inventory Turnover 06/30/25 - - 03/31/25 - 12.96 12/31/24 - 13.62 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©